Zuko Komisa

- Regulators warn against using, prescribing, or dispensing iDEXIS Semaglutide and Tirzepatide.
- The weight-loss and diabetes medications were pulled by SAHPRA in June 2026 due to extreme safety threats.
- Healthcare workers stocking or distributing these items face severe disciplinary and legal action.
South African health regulators have issued an urgent warning to the public and medical professionals to immediately stop using, prescribing, or dispensing recalled batches of Semaglutide and Tirzepatide.
Although manufactured to treat diabetes, these specific iDEXIS-branded medications have become highly popular for weight loss.
The joint directive from the country’s top medical and pharmacy boards follows an official recall initiated by the South African Health Products Regulatory Authority (SAHPRA) in June 2026.
Officials stressed that distributing these products deliberately compromises patient welfare.
“The continued use, prescription and dispensing of these products pose a severe risk to patients’ safety and/or users. Any healthcare professional found to have dispensed, prescribed or kept stock of the recalled products will face disciplinary action…”
Doctors and pharmacists who ignore the mandate face harsh penalties under the Medicines and Related Substances Act.
Authorities confirmed that any practitioners handling the banned stock are knowingly endangering public health and will be subject to immediate disciplinary procedures.



